A simple blood test can let people know if they will develop the disease or not, but since there is no cure, many opt not to have it. Patients usually die within 10 to 30 years of its onset.
PUTTING PATIENTS BACK IN CONTROL: As Huntington's disease progresses, many suffer from chorea, or jerky, involuntary movements throughout the body. Tetrabenazine (Xenazine) is the first drug approved by the FDA to treat chorea in HD patients. It works by decreasing the amount of dopamine in the brain. Dopamine is a neurotransmitter that allows certain nerve cells to communicate. In people who have HD, dopamine is overactive, resulting in the abnormal movements. By decreasing dopamine, the movements are thereby also decreased.
A randomized, double-blind, placebo-controlled clinical trial investigated the safety and effectiveness of the drug. The involuntary movements of patients who received tetrabenazine reduced on average by 25 percent. In addition, patients who took the drug were six times as likely to be considered by their doctors to have improved significantly. Sixteen sites across the county conducted the study, which involved 84 patients.
FOR MORE INFORMATION, PLEASE CONTACT:
Deborah Song, Media Relations
Rush University Medical Center
Chicago, IL
(312) 942-0588
deb_song@rush.edu